|
| 36888930 | Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. | J Clin Oncol | 2023 |
| 36255372 | Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial. | Clinical Cancer Research | 2023 |
| 37807952 | -class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. | | 2023 |
| 37726298 | In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. | | 2023 |
| 37703506 | Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. | J Clin Oncol | 2023 |
| 35728048 | Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. | Blood Adv | 2022 |
| 34658441 | A Primer on Chimera Associated Receptor T-Cells. | Missouri Medicine | 2021 |
| 34172037 | Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. | BMC Cancer | 2021 |
| 33631112 | Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. | Lancet Haematology,The | 2021 |
| 34156898 | Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. | J Clin Oncol | 2021 |
| 33259589 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. | Blood | 2021 |
| 33231464 | pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. | Molecular Pharmaceutics | 2021 |
| 33416412 | Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. | Leukemia and Lymphoma | 2021 |
| 32552301 | Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. | Leukemia and Lymphoma | 2020 |
| 32031039 | Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. | Leukemia and Lymphoma | 2020 |
| 32912820 | Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 30787177 | CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. | Mol Cancer Ther | 2019 |
| 30766403 | Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA. | | 2018 |
| 30271822 | Comparison of Bone Marrow Biopsy Specimens Obtained Using a Motorized Device and Manual Biopsy Systems. | Asia-Pacific Journal of Oncology Nursing | 2018 |
| 30114559 | CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. | Leuk Res | 2018 |
| 29097499 | Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. | Haematologica | 2018 |
| 29370782 | Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. | BMC Cancer | 2018 |
| 29414775 | The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling. | Journal of Biological Chemistry | 2018 |
| 29238066 | Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS). | Blood Cancer Journal | 2017 |
| 28684528 | Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation. | Cancer Research | 2017 |
| 27734609 | A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. | Cancer Med | 2016 |
| 26968357 | Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. | Lancet Oncol | 2016 |
| 27358895 | Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature. | Stem Cell Investigation | 2016 |
| 26442612 | Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. | Leukemia | 2016 |
| 26500138 | Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. | Leukemia | 2016 |
| 26686043 | Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. | Lancet Haematology,The | 2015 |
| 30766092 | An Electronic Chemotherapy Ordering Process and Template. | | 2015 |
| 25572917 | A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. | British Journal of Haematology | 2015 |
| 26397138 | Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. | Oncotarget | 2015 |
| 23566162 | A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells. | Leuk Lymphoma | 2014 |
| 24393720 | Retinoic acid signaling pathways in development and diseases. | Bioorganic and Medicinal Chemistry | 2014 |
| 23288782 | A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. | Molecular Cancer Therapeutics | 2013 |
| 23798029 | Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. | Pharmacotherapy | 2013 |
| 23874588 | Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. | PLoS ONE | 2013 |
| 23390194 | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. | Blood | 2013 |
| 23617429 | Boron chemicals in diagnosis and therapeutics. | Future Medicinal Chemistry | 2013 |
| 23088873 | HDAC inhibitors and chaperone function. | | 2012 |
| 23009932 | Role of additional novel therapies in myeloproliferative neoplasms. | Hematology/Oncology Clinics of North America | 2012 |
| 22020939 | Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells. | J Biol Chem | 2011 |
| 21532034 | Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. | Journal of Biological Chemistry | 2011 |
| 21706446 | Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells. | Journal of Cell Communication and Signaling | 2011 |
| 20197389 | 2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the beta-catenin-E-cadherin axis. | Molecular Cancer Therapeutics | 2010 |
| 20001244 | p38 in chronic myelogenous leukemia: a target and a possible biomarker. | Leukemia and Lymphoma | 2009 |
| 19747365 | Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. | British Journal of Haematology | 2009 |
| 18713449 | Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia? | Journal of Translational Medicine | 2008 |